anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intervention will include having participants will be fitted for an adjustable compression wrap. They will be required to wear the adjustable compression wrap during the decongestive progressive resistance exercise program and will continue wearing their compression sleeve at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness centre or at home.
PURPOSE: A method of producing an extract of a plant belonging to Panax genus through heat treatment, physicochemical treatment such as acid treatment and biological treatment such as lactic acid bacteria and intestinal bacteria culture is provided. The composition containing the plant extract has inhibitory activity against cancer or disease associated with allergy and thus can be effectively used as a therapeutic agent associated therewith. CONSTITUTION: For acid and biological treatment, a plant belonging to Panax genus is cultured 1 to 50 times by volume with an acid and neutralized with a base. The extract is then cultured with lactic acid bacteria or intestinal bacteria. For heat and biological treatment, the plant is heated at 110 to 180deg.C for 0.5 to 20hr, the extract is cultured with lactic acid bacteria or intestinal bacteria. The component ratio of the saponin(a sum of ginsenoside Rk2, Rh3, PPD and DHPPD/a sum of ginsenoside Rg3, Rg5 and Rk1) is 0.1 or more. The plant is one or more of Panax ginseng, Panax quinquefolia, Panax notoginseng, Panax japonica, Panax trifolia, Panax pseudoginseng, Panax vietnamensis, Panax wangianus and Panax angustifolium.
This study utilizes on open phase of 4-sessions of cognitive-behavior therapy for smoking cessation that is combined with open pharmacotherapy (selected by participants in collaboration with the study medical team: nicotine patch, varenicline, or bupropion). Session topics include educational (e.g., health risks of smoking, effectiveness of different treatment approaches), motivational enhancement (e.g., identifying personally relevant benefits of quitting, and costs of continuing to smoke), and cognitive-behavioral elements (e.g., identifying smoking triggers, developing coping strategies for these triggers, planning for high risk situations, relapse prevention). The study therapists will also make a supportive phone call on the day of the quit attempt, with repeated check-in calls over the quit window (i.e., weeks 4-6) as needed for individuals having difficulties reaching abstinence. Participants who fail to achieve smoking cessation during the quit period window will be referred for clinical treatment as desired in the center the study is conducted in or an alternative site.

Following successful smoking abstinence at Week 0 (Week 0 is defined by 24 hr abstinence within a two-week grace period of the target date), participants will be randomized to the study drug condition (50 mg DCS or matching placebo) combined with cue-exposure therapy (CET). CET is manualized and will have four modalities: (1) exposure to slides of smoking (pictorial), (2) exposure to emotions and imagined situations that most reliably trigger an urge to smoke (emotional/imaginal), (3) exposure to a participant's own cigarettes and pack (in vivo),70 and (4) personalized and immersive 360° VR exposure (participants select the VR scene-e.g., break time outside work, evening party, car ride that best corresponds to their highest craving situation). CET sessions are scheduled for the quit week, one week later, and again 8 weeks later. Smoking cessation assessments continue across 24 weeks of follow-up.
The effectiveness of STRATTERA in the treatment of ADHD was established in 2 randomized, double–blind, placebo–controlled clinical studies of adult patients, age 18 and older, who met DSM–IV criteria for ADHD.

Signs and symptoms of ADHD were evaluated using the investigator–administered Conners Adult ADHD Rating Scale Screening Version (CAARS), a 30–item scale. The primary effectiveness measure was the 18–item Total ADHD Symptom score (the sum of the inattentive and hyperactivity/impulsivity subscales from the CAARS) evaluated by a comparison of mean change from baseline to endpoint using an intent–to–treat analysis.

In 2 identical, 10–week, randomized, double–blind, placebo–controlled acute treatment studies (Study 5, N=280; Study 6, N=256), patients received either STRATTERA or placebo. STRATTERA was administered as a divided dose in the early morning and late afternoon/early evening and titrated according to clinical response in a range of 60 to 120 mg/day. The mean final dose of STRATTERA for both studies was approximately 95 mg/day. In both studies, ADHD symptoms were statistically significantly improved on STRATTERA, as measured on the ADHD Symptom score from the CAARS scale.

Examination of population subsets based on gender and age (<42 and ≥42) did not reveal any differential responsiveness on the basis of these subgroupings. There was not sufficient exposure of ethnic groups other than Caucasian to allow exploration of differences in these subgroups.
OBJECTIVES: The most effective treatment for end-stage renal failure is renal transplant. Nonadherence to medication is one of the most important factors in organ rejection and an important problem in pediatric renal transplant and an important cause of graft failure. Adherence is the most important modifiable factor that affects treatment outcomes. Factors such as low education level and socioeconomic level, complexity of the treatment, lack of belief in the effectiveness of the treatment, cost, insufficient education, drug toxicity, and adverse effects negatively affect adherence to treatment. Although medication adherence has been studied in pediatric patients, conflicting results remain on which practices are effective. In this systematic review study, we aimed to determine which interventions are effective in increasing medication adherence in pediatric renal transplant.
MATERIALS AND METHODS: We searched for randomized, nonrandomized, and other interventional studies conducted between 1980 and 2024 through PubMed, Cochrane, EBSCO, SCOPUS, Web of Science, and National Thesis Center and TÜBİTAK (TR Index) databases. We searched the following medical subjects headings, which included Turkish science terms: "renal transplantation" AND ("medication" OR "immunosuppressive") AND ("compliance" OR "adherence") AND ("child" or "pediatrics"). We included randomized controlled trials, quasi-experimental, and interventional studies on individuals aged <18 years with only renal transplant or with other solid-organ transplants and immunosuppressive treatment. We also examined references of review studies. PRISMA guide was used in reporting the study.
RESULTS: Our search identified 970 articles, with 10 studies that met the inclusion criteria. Only 1 study included children under the age of 12 years was found to be eligible after quality assessment for systematic review. The intervention in this study was based on the self-management model.
CONCLUSIONS: Multicomponent interventions may be useful to improve medication adherence in children with renal transplant.
Adults: The usual dosage for persons 13 years of age and over is 1 mL buprenorphine hydrochloride injection (0.3 mg buprenorphine) given by deep intramuscular or slow (over at least 2 minutes) intravenous injection at up to 6-hour intervals, as needed. Repeat once (up to 0.3 mg) if required, 30 to 60 minutes after initial dosage, giving consideration to previous dose pharmacokinetics, and thereafter only as needed. In high-risk patients (e.g., elderly, debilitated, presence of respiratory disease, etc.) and/or in patients where other CNS depressants are present, such as in the immediate postoperative period, the dose should be reduced by approximately one-half. Extra caution should be exercised with the intravenous route of administration, particularly with the initial dose.

Occasionally, it may be necessary to administer single doses of up to 0.6 mg to adults depending on the severity of the pain and the response of the patient. This dose should only be given IM and only to adult patients who are not in a high risk category (see WARNINGS and PRECAUTIONS). At this time, there are insufficient data to recommend single doses greater than 0.6 mg for long-term use. 

Children: Buprenorphine hydrochloride has been used in children 2 to 12 years of age at doses between 2 to 6 micrograms/kg of body weight given every 4 to 6 hours. There is insufficient experience to recommend a dose in infants below the age of two years, single doses greater than 6 micrograms/kg of body weight, or the use of a repeat or second dose at 30 to 60 minutes (such as is used in adults). Since there is some evidence that not all children clear buprenorphine faster than adults, fixed interval or "round-the-clock" dosing should not be undertaken until the proper inter-dose interval has been established by clinical observation of the child. Physicians should recognize that, as with adults, some pediatric patients may not need to be remedicated for 6 to 8 hours.

Safety and Handling: Buprenorphine hydrochloride injection is supplied in sealed cartridges and poses no known environmental risk to health care providers. Accidental dermal exposure should be treated by removal of any contaminated clothing and rinsing the affected area with water.

Buprenorphine is a potent narcotic, and like all drugs of this class has been associated with abuse and dependence among health care providers. To control the risk of diversion, it is recommended that measures appropriate to the health care setting be taken to provide rigid accounting, control of wastage, and restriction of access.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
1,195,050. Artichoke and fennel extracts. SOC. CIVILE DE RECHERCHE PHARMACEUTIQUE ET THERAPEUTIQUE. 21 Sept., 1967 [23 Sept., 1966; 20 Dec., 1966], No. 43075/67. Heading A5B. Despides and flavonoids are obtained from artichoke or fennel plants by amethod comprising: a) extracting said plants with MeOH and/or Et OH, separating the alcohol(s) and repeating the extraction procedure at least once upon the residue and combining the alcoholic extracts, (b) adding to the combined extract at least one hydrophobic solvent e.g. diethyl ether, petroleum ether or hexane, (c) extracting the resulting mixture with water at not greater than room temperature, (d) concentrating the resulting aqueous phase at a temperature <40‹C, (e) taking up the concentrate in MeOH or EtOH, separating the alcohol and repeating the treatment on the residue, and combining the alcohol fractions, (f) adding anhydrous diethyl ether to the combined (fractions to precipitate the desired principles, (g) decanting the supernatant liquid, (h) adding further anhydrous diethyl ether to the precipitate to form a suspension, allowing the suspension to settle and decanting the supernatant liquid, (i) repeating said suspension forming and decanting steps a number of times, and (j) finally drying the precipitate. Freshly out plants are preferably employed in the above method, a modified process in which steps (to) and (e) above are omitted being employed when dried plants are extracted. Steps (a) and (e) may be effected at a temperature in the range from and including ambient temperature and the boiling point of the alcoholic solvent. The aqueous phase may be concentrated by evaporation under reduced pressure, precipitation may be effected at a temperature not exceeding ambient temperature and the final precipitate may be dried by infra-red radiation. The watersoluble fennel and artichoke extracts are used for the treatment of hepatic affections, hypocholesterolemia and renal insufficiency by oral or rectal administration in the form of tablets, sweetened granules, packets of powder, effervescent tablets and drinking ampoules.
Follow the below steps to prepare TNKase for administration:

Using a sterile syringe, aseptically withdraw 10 mL of Sterile Water for Injection, USP, from the supplied diluent vial. Only use the supplied Sterile Water for Injection, USP for reconstitution.

  * Aseptically reconstitute the TKNase vial with 10 mL Sterile Water for Injection, USP by directing the stream into the lyophilized powder to obtain a final concentration of 5 mg/mL. Slight foaming upon reconstitution is not unusual; any large bubbles will dissipate if the product is allowed to stand undisturbed for several minutes.
  * Gently swirl until contents are completely dissolved. DO NOT SHAKE. The reconstituted preparation results in a colorless to pale yellow transparent solution.
  * Determine the appropriate dose of TNKase [see Dosage and Administration (2.1)] and withdraw this volume (in milliliters) from the reconstituted vial with the syringe. Discard any unused solution.
PURPOSE: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is characterized by a multiform clinical presentation requiring a differentiated treatment based on different phenotypes including the psychosocial and sexual domains. The aim of this study was assessing the complex correlations between somatic, psychological, and sexual symptoms of CP/CPPS patients.
MATERIALS AND METHODS: We performed a cross-sectional study on patients attending a Prostatitis Clinic. Patients were administered the following questionnaires: National Institutes of Health- Chronic Prostatitis Symptom Index (NIH-CPSI), International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF), Premature Ejaculation Diagnostic Tool (PEDT), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder 7-item (GAD-7), Oxford Happiness Questionnaire (OHQ), and Temperament Evaluation of Memphis, Pisa, Paris and San Diego Autoquestionnaire (TEMPS-A).
RESULTS: Linear regression analyses show highly significant correlations between scores of the NIH-CPSI and the scores of the GAD-7, PHQ-9 and OHQ psychometric questionnaires. IPSS scores correlate significantly with the psychometric scores only when a non-parametric analysis is performed. IIEF and PEDT sexual function scores did not correlate with any of the psychometric tests. NIH-CPSI scores correlate positively with most of the TEMPS-A profiles but the hyperthymic profile correlated negatively with the total and QoL NIH-CPSI and with PEDT scores.
CONCLUSIONS: Scores measuring anxiety, depression, and psychological well-being in patients with CP/CPPS are strictly correlated with prostatitis-like symptoms although they are poorly correlated with symptoms of prostatism, as measured by IPSS, and not correlated with scores of sexual dysfunctions, as measured by IIEF and PEDT. A hyperthymic temperament may increase resilience against the disease.
Patients receive TAS-102 PO BID on days 1-5 and oxaliplatin IV over 2 hours on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
HIV-related risk survey subjects recruited annually for 4 years: N = 1280-2880 (20-30 members of the population of focus per 2-3 congregation venues, per site, per year). These subjects will complete a survey designed to assess HIV-related risk. In the fourth and final year only, HIV Antibody \[Ab\] assays will also be conducted with survey participants to assess HIV serostatus. The survey and HIVAb assay data will be used to evaluate the intervention within and across sites.
A total of 50 patients, aged between 18-65, who were diagnosed with symptomatic irreversible pulpitis of the mandibular molar tooth, were included in this study. The patients were allocated in two groups according to the randomization blocks, with a total of 25 patients in each group. In IANB + BI anesthesia techniques, a total of approximately 2.8 ml of anesthetic solution, 1.8 ml + 1 ml, was applied, while for BI + ILI, a total of approximately 1.72 ml, 1 ml + 0.72 ml, was administered. After the anesthesia, a rubber dam was placed on the associated tooth of the patient for root canal treatment, the endodontic access cavity was opened, and canal preparation procedures were started. The pain levels felt by the patients during the endodontic treatment stages (starting the treatment, opening the endodontic access cavity and pulp extirpation) were determined by Heft-Parker VAS (HP-VAS) scale. Anesthesia was considered successful in patients who felt no pain (HP-VAS ratio = 0) or mild pain (HP-VAS ratio ≤ 54) during the procedures.
The present invention is concerned with inactivated adjuvanted influenza vaccines. The present invention provides a vaccine that overcomes many of the drawbacks of existing inactivated influenza vaccines. The present invention provides an inactivated influenza vaccine, comprising beta propiolactone (BPL) inactivated whole influenza virus and comprising, as adjuvant, one or more mono-or disaccharide derivatives having at least one but not more than N-1 fatty acid ester groups and, optionally, one but not more than N-1 sulphate ester groups, wherein N is the number of hydroxyl groups of the mono-or disaccharide from which the derivative is derived. The influenza virus in a vaccine according to the invention is preferably cell culture derived. Methods for producing influenza virus in cell culture are known in the art. The virus may be grown on cells of mammalian, avian, or human origen, such as Madin Darby Canine Kidney (MDCK), Vero, MDBK, CLDK, EBx or PerC6 cells.
This warning does not apply to Rh o(D)-negative patients treated for the suppression of Rh isoimmunization. 

  * Intravascular hemolysis (IVH) leading to death has been reported in patients treated with WinRho ®SDF for immune thrombocytopenic purpura (ITP). 
  * IVH can lead to clinically compromising anemia and multi-system organ failure including acute respiratory distress syndrome (ARDS).
  * Serious complications including severe anemia, acute renal insufficiency, renal failure and disseminated intravascular coagulation (DIC) have also been reported.
  * Closely monitor patients treated with WinRho ®SDF for ITP in a healthcare setting for at least 8 hours after administration. A dipstick urinalysis to monitor for hematuria and hemoglobinuria is to be performed at baseline and then after administration at 2 hours, 4 hours and prior to the end of the monitoring period. Alert patients and monitor the signs and symptoms of IVH including back pain, shaking chills, fever, and discolored urine or hemoglobinuria. Absence of these signs and/or symptoms of IVH within 8 hours do not indicate IVH cannot occur subsequently. If signs and/or symptoms of IVH are present or suspected after WinRho ®SDF administration, post-treatment laboratory tests should be performed including plasma hemoglobin, haptoglobin, LDH, and plasma bilirubin (direct and indirect). 
  * If ITP patients are to be transfused after receiving WinRho ®SDF, use Rh o(D)-negative red blood cells (PRBCs) so as not to exacerbate ongoing hemolysis.
FIELD: medicine, pharmacy, biotechnology. SUBSTANCE: invention relates to stabilization of "lipid : DNA" in the process of spraying. Invention involves pharmaceutical compound including plasmid DNA carrying gene, cationic lipid, neutral lipid and trypton or glutamic acid and spraying suspension including cationic lipid bis-(guanidinium)-trencholesterol, neutral colipid dioleoylphosphatidylethanolamine or its analogue and plasmid DNA carrying gene also. Invention provides the development of medicinal form used in gene therapy. EFFECT: improved stability, valuable properties of composition. 11 cl, 5 dwg
The invention relates to a traditional Chinese medicine composition for treating gynecological diseases and a production method thereof, which belong to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine mainly comprises Baikal skullcap root, Chinese gall, glabrous greenbrier rhizome, cnidium fruit and dittany bark. The production method comprises the following process steps of weighing according to the recipe, backflow extracting, filtering, concentrating, sterilizing, sub-packaging, and the like. The traditional Chinese medicine has the effects of clearing away the heat evil and expelling superficial evils, eliminating dampness and reducing leucorrhea, and destroying parasites and reliving itching. The medicine which is used for pruritus vulvae and leucorrhea abnormality caused by the damp heat downflow of women is suitable for pruritus vulvae, even pains and itching, large quantity of leucorrhea, stink odor, vexation and bitter taste, and the symptoms of colpitis mycotica and trichomonal vaginitis. Compared with other medicines for treating the similar diseases, the medicine which greatly improves the specificity of medicine application has a greatly improved curative effect. The traditional Chinese medicine and the production method have unique recipe and simple and feasible production method, and have convenient use, and safety and reliability.
BACKGROUND: Chronic low-grade inflammation is related to bone metabolism in patients with type 2 diabetes mellitus (T2DM). However, credible data indicating the relationship between inflammation and fragility fracture risk in postmenopausal anemic females with T2DM are sparse. The current study sought to investigate the relationships between the systemic immune-inflammatory index (SII) and fragility fracture events, as well as the future 10-year fragility fracture probability evaluated using the fracture risk assessment tool (FRAX) in postmenopausal females with T2DM.
METHODS: According to the tertiles of SII, 423 postmenopausal females with T2DM were divided into three groups: low-level (≤ 381.32, n = 141), moderate-level (381.32-629.46, n = 141), and high-level (≥ 629.46, n = 141). All participants were followed up for 7 years with a median of 46.8 months (1651 person-years). The association between SII and fragility fracture risk was assessed.
RESULTS: Of 423 subjects, 75 experienced a fragility fracture event. Spearman partial correlation analysis revealed that SII was negatively related to bone mineral density (BMD) and was positively associated with the future 10-year probability of major osteoporotic fracture (MOF) and hip fracture (HF). Restricted cubic spline (RCS) analysis revealed a positive correlation between SII and fragility fracture risk in an approximately inverted J-shaped dose-response pattern (P for overall < 0.0001). Multivariate Cox regression analysis demonstrated that patients with a high SII presented a greater risk of fragility fractures (P = 0.011). Stratified analysis revealed that fragility fractures in the high-level SII were predominantly associated with anemia with an increase of 4.15 times (P = 0.01). Kaplan‒Meier analysis indicated a greater cumulative incidence of fragility fractures in patients with a high SII (log-rank, all P = 0.0012). Receiver operating characteristic (ROC) analysis indicated an optimal SII cut-off value of 537.34, with an area under the curve (AUC) of 0.646, a sensitivity of 60%, and a specificity of 64.1% (P < 0.001).
CONCLUSION: The SII revealed a significant positive association with a real-world fragility fracture event and a future 10-year fragility fracture probability in postmenopausal females with T2DM, particularly evident in individuals with anemia. Therefore, monitoring the SII and hemoglobin in postmenopausal older women with T2DM is helpful in routine clinical practice to identify individuals at high risk for fragility fractures and to promptly execute appropriate fracture intervention procedures.